NEWS
Latest insights in pharmacology
Stay informed and join the conversation on advancing healthcare.

Is my patient cheating?
Even patients who follow their prescribed medication regimen may experience vastly different drug responses, from life-threatening adverse effects to complete lack of efficacy—highlighting the critical role of factors like drug-drug interactions, organ function, and genetic variability in treatment outcomes.
- Science to Practice

Increased risk of hospitalisation due to drug interactions in older adults
Drug interactions in older adults can lead to serious adverse events, longer hospital stays, and reduced quality of life.
- Science to Practice

Valproic acid and reproductive risks – the full story has not yet been told
Recent research indicates no evidence linking paternal valproic acid use before conception to increased risks of congenital malformations or neurodevelopmental disorders in offspring. Current data does not support major concerns.
- Science to Practice

All hope is not lost – tackling the global kidney disease burden with new therapeutics
New therapies, like SGLT2 inhibitors and GLP-1 receptor agonists, offer hope by slowing kidney disease progression and improving outcomes.
- Science to Practice

Tetracycline antibiotics may be used for up to three weeks also when breastfeeding
Tetracycline antibiotics can be used for up to three weeks during breast-feeding, as low milk excretion and minimal reported adverse effects have extended the recommended use.
- Science to Practice

Why should I bother with pharmacogenetics?
At least one actionable pharmacogenetic mutation is present in 97-99% of population (1,2) and more than half of them had three or more mutations (2).
- Science to Practice

Herbal products containing ashwagandha and turmeric/curcumin linked to liver injury
Ashwagandha may cause cholestatic hepatitis and elevated liver enzymes.
- Science to Practice

Genetic variability affects outcomes of drug therapy
Drug therapies don’t always work as expected. For some patients, the drugs have no effect, while others may experience severe adverse reactions.
- PROF. MIKKO NIEMI
- Interview

“Our product development is foresighted”
Markus Jansén, M.Sc. (Tech.), began his new role in April, motivated by the meaningful impact of his work.
- CPO MARKUS JANSÉN
- Our People

Vaaka Partners to invest in Medbase
Finland is exceptionally advanced in utilising user-friendly, high-quality drug information in everyday clinical work. This is largely due to…
- Interview